Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$74.55
+1.1%		$70.71
$27.87
▼
$109.00
$2.52B1.14592,277 shs340,346 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
+1.06%+0.03%+5.34%+14.90%+154.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$74.55
+1.1%		$70.71
$27.87
▼
$109.00
$2.52B1.14592,277 shs340,346 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
+1.06%+0.03%+5.34%+14.90%+154.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.77
Moderate Buy$141.5089.81% Upside

Current Analyst Ratings Breakdown

Latest NKTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/21/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$65.00
7/22/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$153.00
6/2/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$55.23M46.08N/AN/A$26.45 per share2.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$164.08M-$6.70N/AN/AN/A-287.84%-37.87%-25.67%11/5/2026 (Estimated)

Latest NKTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$1.97-$1.23+$0.74-$1.23$10.43 million$10.13 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
10.42
10.42

Institutional Ownership

CompanyInstitutional Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%

Insider Ownership

CompanyInsider Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
22034.14 million33.29 millionOptionable

Recent News About These Companies

Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
August 27 at 3:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nektar-nktr-billion-dollar-balance-135659492.html
Nektar Therapeutics (NASDAQ:NKTR) Upgraded at TD Cowen
August 27 at 1:49 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30985326
AWM Investment Company Inc. Acquires Shares of 20,925 Nektar Therapeutics $NKTR
August 26 at 3:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-awm-investment-company-inc-acquires-shares-of-20925-nektar-therapeutics-nktr-2026-08-26/
Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
August 25 at 8:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/nektar-announces-publication-in-the-lancet-of-positive-phase-2b-rezolve-ad-16-week-induction-results-of-rezpegaldesleukin-in-moderate-to-severe-atopic-dermatitis-302858888.html
Nektar Therapeutics (NASDAQ:NKTR) Upgraded by TD Cowen to Strong-Buy Rating
August 25 at 6:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-nektar-therapeutics-nasdaq-nktr-upgraded-by-td-cowen-to-strong-buy-rating-2026-08-25/
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at JPMorgan Chase & Co.
August 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30977403
Nektar (NKTR) Q2 2026 Earnings Call Transcript
August 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nektar-nktr-q2-2026-earnings-233402905.html
JPMorgan Chase & Co. Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR)
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/jpmorgan-chase-co-initiates-coverage-on-nektar-therapeutics-nasdaqnktr-2026-08-21/
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $13,388.28 in Stock
August 21, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nktr-insider-buying-and-selling-2026-08-21/
HC Wainwright Issues Negative Outlook for NKTR Earnings
August 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973404
Top Nektar Therapeutics Insiders Quietly Cash In on Recent Stock Moves
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/top-nektar-therapeutics-insiders-quietly-cash-in-on-recent-stock-moves-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of Stock
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/nektar-therapeutics-nasdaqnktr-insider-jonathan-zalevsky-sells-186-shares-of-stock-2026-08-20/
Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-nektar-therapeutics-nasdaqnktr-ceo-sells-3008764-in-stock-2026-08-20/
HC Wainwright Issues Pessimistic Forecast for NKTR Earnings
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-forecast-for-nktr-earnings-2026-08-19/
Nektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway
August 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/ratings/nektar-therapeutics-initiated-at-buy-on-rezpegs-advancing-pivotal-programs-and-solid-cash-runway-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Nektar Therapeutics (NASDAQ:NKTR) Receives $150.00 Average PT from Analysts
August 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30966210
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise
August 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nektar-therapeutics-nktr-could-52-020915503.html
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch
August 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nektar-therapeutics-nktr-stock-looks-151217411.html
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936885-nektar-maintaining-strong-buy-rating-due-to-rezpeg-catalyst-another-coming
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus
August 14, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2975069/nektar-q2-earnings-beat-estimates-revenues-lag-pipeline-in-focus?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2975069
Nektar Therapeutics (NKTR) Q2 2026
August 14, 2026  |  247wallst.comhttps://247wallst.com/companies/nktr/earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$74.55 +0.78 (+1.06%)
Closing price 08/27/2026 04:00 PM Eastern
Extended Trading
$74.80 +0.25 (+0.34%)
As of 07:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas